Tessalon — Competitive Intelligence Brief

Tessalon (benzonatate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-narcotic Antitussive [EPC]. Area: Respiratory.

marketed Non-narcotic Antitussive [EPC] Sodium channel protein type 5 subunit alpha Respiratory Small molecule

Target snapshot

Tessalon (benzonatate) — Generic (originally Pfizer).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tessalon TARGET	benzonatate	Generic (originally Pfizer)	marketed	Non-narcotic Antitussive [EPC]	Sodium channel protein type 5 subunit alpha	1958-01-01
Ranexa	RANOLAZINE	Menarini Intl	marketed	Anti-anginal [EPC]	Sodium channel protein type 5 subunit alpha	2006-01-01
Naropin	ROPIVACAINE	Fresenius Kabi	marketed	Amide Local Anesthetic	Sodium channel protein type 5 subunit alpha	1996-01-01
Cerebyx	FOSPHENYTOIN	Pfizer	marketed	Anti-epileptic Agent	Sodium channel protein type 5 subunit alpha	1996-01-01
Decabid	INDECAINIDE	Eli Lilly	marketed		Sodium channel protein type 5 subunit alpha	1989-01-01
ENCAINIDE	ENCAINIDE		marketed	encainide	Sodium channel protein type 5 subunit alpha	1986-01-01
Ranexa	Ranexa	Midwest Cardiovascular Research Foundation	marketed		Multidrug resistance protein 1, Potassium voltage-gated channel subfamily H member 2, Sodium channel protein type 5 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2038-01-24 — Ranexa · 11510878 · Formulation · US
• 2038-01-24 — Ranexa · 12161761 · Formulation · US
• 2038-01-24 — Ranexa · 10898444 · Formulation · US

Sponsor landscape (Non-narcotic Antitussive [EPC] class)

1. Generic (originally Pfizer) · 1 drug in this class